Bilateral multicystic dysplastic kidney

Summary

Bilateral multicystic dysplastic kidney (MONDO:0019982) is a disease and 15 clinical trials. Top therapeutic interventions include carfilzomib, daratumumab, and lenalidomide. A subtype of multicystic dysplastic kidney — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bilateral multicystic dysplastic kidney
Mondo ID	MONDO:0019982
Orphanet	97364
SNOMED CT	717749002
UMLS	C1840451
MedGen	333563
GARD	0009517
Is cancer (heuristic)	no

Also known as: bilateral MCDK · bilateral multicystic renal dysplasia · MRD · Pelvi-ureteric junction obstruction · PUJO

Disease family

This is a subtype of multicystic dysplastic kidney. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › cystic kidney disease › multicystic dysplastic kidney › bilateral multicystic dysplastic kidney

Related subtypes (1): unilateral multicystic dysplastic kidney

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	10
PHASE2	3
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06409702	PHASE4	RECRUITING	Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
NCT05536505	PHASE2	RECRUITING	Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05736978	PHASE2	RECRUITING	Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
NCT07120698	PHASE2	RECRUITING	Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
NCT07371247	EARLY_PHASE1	ENROLLING_BY_INVITATION	Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
NCT06822270	Not specified	ACTIVE_NOT_RECRUITING	Different Surgical Modalities in the Management of Pelvi-ureteric Junction Obstruction
NCT06918262	Not specified	RECRUITING	Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer
NCT07112612	Not specified	NOT_YET_RECRUITING	Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer
NCT07215494	Not specified	NOT_YET_RECRUITING	A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
NCT07254156	Not specified	NOT_YET_RECRUITING	A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
NCT02872662	Not specified	COMPLETED	Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
NCT03620955	Not specified	UNKNOWN	Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML
NCT03971305	Not specified	UNKNOWN	A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
NCT04503330	Not specified	UNKNOWN	Buccal Mucosal Graft for the Repair of Iatrogenic Pelviureteric Junction Obstruction or Ureteric Stricture.
NCT07475923	Not specified	WITHDRAWN	Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARFILZOMIB	4	1
DARATUMUMAB	4	1
LENALIDOMIDE	4	1
SELINEXOR	4	1
CHEMBL5204484	0	1